ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Protective effects of the Bupi Yishen formula on renal fibrosis through PI3K/AKT signaling inhibition

Liu, Bingran; Deng, Jiankun; Jie, Xina; Lu, Fuhua; Liu, Xusheng*; Zhang, Difei*广东省人民医院; 广州中医药大学
Journal of Ethnopharmacology2022-7-15DOI: 10.1016/j.jep.2022.115242
4被引28阅读
引用收藏
分享

摘要

Ethnopharmacological relevance: The Bupi Yishen Formula (BYF) is a patented Chinese herbal compound that has been long used to treat chronic kidney disease (CKD) in the clinic. However, its main active ingredients and underlying mechanisms remain to be elucidated. @@@ Aim: Identify the major active ingredients of BYF and investigate its protective effects and specific molecular mechanisms in renal fibrosis. @@@ Methods: First, we performed network pharmacology analysis combined with molecular docking to predict the main active compounds, potential therapeutic targets, and intervention pathways that might exert the antifibrotic effect of BYF in the kidney. Then, we validated the predictions in both adenine-induced CKD rats and TGF beta 1-induced HK-2 cells. @@@ Results: A total of 233 common analyses. Then, GO and KEGG functional enrichment analyses indicated that the renoprotection conferred by BYF against renal fibrosis was mainly associated with the PI3K/AKT signaling. Besides, the molecular docking showed that the 10 main active compounds of BYF were closely docked with three main PI3K/AKT pathway proteins. During the experimental validations, BYF improved renal impairment and alleviated fibrosis by inhibiting the PI3K/AKT signaling activity in the kidney of adenine-induced CKD model rats. Moreover, increased PI3K/AKT signaling activation was associated with fibrotic phenotype changes in adenine-induced CKD rats and TGF beta 1-induced HK-2 cells. On the other hand, BYF treatment reduced PI3K/AKT signaling activation and decreased renal fibrogenesis in a dose-dependent manner, thereby indicating that PI3K/ AKT signaling was essential for BYF to exert its anti-fibrotic effects. Finally, the inhibitory effect of BYF on renal fibrogenesis was not enhanced while blocking the PI3K/AKT pathway with a broad spectrum PI3K inhibitor (LY294002). @@@ Conclusion: In the present study, we applied a comprehensive strategy based on systemic pharmacology to reveal the anti-fibrotic mechanisms of BYF, at least partially, through the inhibition of PI3K/AKT signaling activation. We also identified BYF as a potential therapeutic agent for renal fibrosis and CKD progression.

学科与关键词

关键词
Renal fibrosisBupi Yishen formulaNetwork pharmacologyMolecular dockingPI3K/AKT signaling
相关
加载中…
  • Fufang Shenhua tablet inhibits renal fibrosis by inhibiting PI3K/AKT
    Li, Run; Shi, Chunru; Wei, Cuiting; Wang, Chao; Du, Hongjian; Liu, Ran; Wang, Xu; Hong, Quan*; Chen, Xiangmei*PHYTOMEDICINE, 2023, 116: 154873.被引 1
  • Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules
    Liu, Bingran; Jie, Xina; Deng, Jiankun; Zhang, Simeng; Lu, Fuhua; Liu, Xusheng*; Zhang, Difei*PHYTOMEDICINE, 2023, 114: 154767.被引 2
  • Chinese herbal decoction astragalus and angelica exerts its therapeutic effect on renal interstitial fibrosis through the inhibition of MAPK, PI3K-Akt and TNF signaling pathways
    Yuan, Hao; Wu, Xuelian; Wang, Xiaomin; Yuan, Chengfu*Genes & Diseases, 2022, 9(2): 510-521.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Ethnopharmacology
发表日期
2022-07-15
卷期
第 293 卷
页码
115242
DOI
10.1016/j.jep.2022.115242
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81904099]; China Postdoctoral Science Foundation [2020M672559]

作者

  • L

    Liu, Bingran (第一作者)

    2 · guangzhou univ chinese med

  • D

    Deng, Jiankun

    2 · guangzhou univ chinese med · shantou cent hosp

查看全部 6 位作者收起作者
  • J

    Jie, Xina

    2 · guangzhou univ chinese med · guangdong prov hosp

  • L

    Lu, Fuhua

    2 · guangzhou univ chinese med · guangdong prov hosp

  • L

    Liu, Xusheng (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • Z

    Zhang, Difei (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417